WO2023053030 - AN IMPROVED PROCESS FOR PURIFICATION OF PROTEIN
National phase entry:
Publication Number
WO/2023/053030
Publication Date
06.04.2023
International Application No.
PCT/IB2022/059238
International Filing Date
28.09.2022
Title **
[English]
AN IMPROVED PROCESS FOR PURIFICATION OF PROTEIN
[French]
PROCÉDÉ AMÉLIORÉ POUR PURIFICATION DE PROTÉINE
Applicants **
KASHIV BIOSCIENCES, LLC
20, New England Avenue
Piscataway, New Jersey 08854, US
Inventors
NARAYAN, Om
802, Anvayaa, Makarba Road, Vejalpur, Ahmedabad, Gujarat
Ahmedabad 380051, IN
GUPTA, Tarun Kumar
A2/43, Orchid Greenfield Applewoods Township, S.P. Ring Road, Ahmedabad, Gujarat
Ahmedabad 380058, IN
THAKKAR, Mayankkumar
C501, Setu Vertica, B/H Vodaphone Tower, Gota, Ahmedabad, Gujarat
Ahmedabad 382481, IN
UPADHYAY, Roshan Ganeshlal
NE/36, Shivanand Apartment,
K K Nagar road, Ghatlodia,
Ahmedabad,
Gujarat
Ahmedabad 380061, IN
Priority Data
202121043959
28.09.2021
IN
202121043962
28.09.2021
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2582 | |
| EPO | Filing, Examination | 22046 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 9280 |
Total: 35106 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to purification process of pharmacologically active IgG1 containing protein comprising at least affinity chromatography followed by mixed-mode chromatography. The present invention providescytotoxic T-lymphocyte-associated 4-immunoglobulin (CTLA4-Ig) fusion protein by using at least affinity chromatography, mixed-mode chromatography and optionally one or more suitable purification steps that provides purified composition of the fusion protein, substantially free of impurities selected from Pre-Peak, product and process related impurities. Further, the present invention provides highly purified CTLA4-Ig fusion protein with reduced heterogeneity.[French]
La présente invention concerne un procédé de purification d'une protéine contenant une IgG1 active du point de vue pharmacologique comprenant au moins une chromatographie d'affinité suivie d'une chromatographie en mode mixte. La présente invention concerne la protéine de fusion de l'immunoglobuline associée à l'antigène 4 de lymphocytes T cytotoxiques (CTLA4-Ig) à l'aide d'au moins une chromatographie d'affinité, une chromatographie en mode mixte et éventuellement une ou plusieurs étapes de purification appropriées qui fournissent une composition purifiée de la protéine de fusion, sensiblement exempte d'impuretés sélectionnées parmi des impuretés associées au produit et au procédé, pré-pic. En outre, la présente invention concerne une protéine de fusion CTLA4-Ig hautement purifiée présentant une hétérogénéité réduite.